At a glance
ClinicalIndex Comparison RecordPhase 2Unknown· 388 target
Drug / intervention
BPB-101drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II, Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BPB-101 in Patients With Advanced Malignant Solid Tumors.
In Brief
A Phase 2 clinical trial evaluating BPB-101 for Solid Tumor. Targeting 388 participants across 4 sites.
Detailed Summary
This is a multi-center, open-label, Phase I/II clinical study of BPB-101 as monotherapy in patients with advanced solid tumors to evaluate the safety, pharmacokinetic characteristics and antitumor activity of BPB-101.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumor
CountriesChina
Collaborators--
Timeline
Phase 2UnknownOverdue
202420252026
Enrollment StartMay 2023
First PostedMay 2023
Primary CompletionAug 2025
Study CompletionSep 2025
TodayJul 2026
First PostedMay 22, 2023
Enrollment StartMay 16, 2023
Primary CompletionAug 2, 2025
Study CompletionSep 1, 2025
TodayJul 1, 2026
Enrollment to primary: 2.2 yearsPosted 3.1 years ago
Interventions
BPB-101drug
Subjects will receive an intravenous infusion of BPB-101 in a pre-set dose escalation until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the trial.